You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The Cambridge, UK-based firm saw double-digit growth in its screening business and declines in its bioproduction and diagnostics businesses.
The company recently inked deals with Mammoth Biosciences and Rutgers University to license a protein discovery platform and gene editing technology.
The company said revenue growth during the year was driven by performance in its research reagents and screening business units.
The company, which recently signed a licensing agreement with Horizon Discovery, just raised $45 million in a Series B financing round.
Exact Sciences CEO Kevin Conroy discussed the firm's pipeline and plans for 2020 and beyond, while NanoString CEO Brad Gray talked about the company's GeoMx digital spatial profiling technology, among other presentations Wednesday.
Horizon also said it will provide access to the technology to business partners for the development of more effective multi-gene knockout cell therapy programs.
In December, the companies agreed to develop CRISPR tools with the aim of generating new engineered cell lines for the biopharmaceutical industry.
The companies will identify and optimize novel CRISPR proteins owned by Mammoth, and then license those proteins to Horizon for use in engineered cell lines.
The Human Protein Atlas was founded in 2003 to map all the human proteins in cells, tissues, and organs using a variety of omics technologies.
New analyses indicate female researchers are publishing less during the coronavirus pandemic than male researchers, according to Nature News.
A study suggests people with the ApoE e4 genotype may be more likely to have severe COVID-19 than those with other genotypes, the Guardian says.
Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.
In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.